Biota moves US research to Australia
18 August, 2004 by Melissa TrudingerBiota (ASX: BTA) will relocate its US research operations to its new facilities in Melbourne in a bid to save costs.
Chemeq confirms details of $50m capital raising
18 August, 2004 by Melissa TrudingerChemeq (ASX: CMQ) has confirmed that its capital raising will include a placement of around AUD$10 million to institutions and sophisticated investors, as well as an underwritten rights offer of around $40 million to existing shareholders.
Proteome Systems gears up for September float
17 August, 2004 by Graeme O'NeillSydney-based proteomics pioneer Proteome Systems lodged a long-awaited prospectus for its initial public offering on the ASX with the Australian Securities and Investment Commission today.
Tissue Therapies' Upton wins award
17 August, 2004 by Melissa Trudinger\Tissue Therapies (ASX: TIS) founder and chief scientist Dr Zee Upton has won the research scientist category for the Smart Women - Smart State awards in Queensland for her work in the area of wound healing and cell culture technologies.
Canada’s agbiotech nursery gives teething lessons
16 August, 2004 by Graeme O'NeillAustralasia’s venture capital-starved biotechnology industries probably need a fairy godmother like Canada’s Foragen Technologies Management.
FDA rejects Cyberonics device, contradicts panel
13 August, 2004 by Staff WritersThe US Food and Drug Administration has refused to approve a pacemaker-like device made by Houston-based Cyberonics to treat depression rejecting the advice of its own panel of experts.
Ag genomics centre heralds toxicity discoveries
13 August, 2004 by Graeme O'NeillTwo years after it was established, the NSW Agricultural Genomics Centre is showing its mettle, announcing the discovery of several DNA markers for genes conferring tolerance to aluminium toxicity.
Xenome CEO steps down as focus moves to US
13 August, 2004 by Melissa TrudingerXenome CEO Dr Tony Evans has stepped down as the company prepares to move into a new phase of development and activity with a focus on opportunities in the US.
UK GPs to test for asthma using Pharmaxis’ Aridol
12 August, 2004 by Renate KrelleHaving recently completed the Phase III clinical trials for its patented asthma prognostic, Aridol, Sydney-based Pharmaxis (ASX: PXS) today announced that the first patients had been enrolled in a major UK clinical study.
Panbio gets FDA approval for second-generation West Nile test
12 August, 2004 by Melissa TrudingerPanbio (ASX:PBO) has received approval from the FDA for an improved diagnostic immunoassay for West Nile Virus (WNV). The new test, which has increased specificity and sensitivity and is easier to use, comes a year after the company received approval for the first WNV test on the market.
Biota wins access to GSK documents
11 August, 2004 by Melissa TrudingerAn affidavit filed on behalf of Biota (ASX: BTA) in the Victorian Supreme Court this week has shown that the amount of money spent by GlaxoSmithKline in promoting Biota's drug Relenza in major markets dropped by 80 per cent in the second flu season after the drug was approved.
Eureka award winner finds chink in parasites' armour
11 August, 2004 by Graeme O'NeillMolecular parasitologist Dr Sabina Belli finds relief from the stresses of a busy research career in kayaking and white-water rafting.
Advice to inventors: if you love it, let it go
11 August, 2004 by Melissa TrudingerPioneering sleep specialist Dr Murray Johns had some good advice yesterday for medical practitioners wanting to commercialise their medical devices and inventions.
Chemeq's fall from grace continues
10 August, 2004 by Graeme O'NeillChemeq’s (ASX:CMQ) prolonged bout of the winter blues have continued even as the first commercial batches of its antimicrobial polymer flow from its new production plant in WA.
Pharmaxis healthy, despite clinical trials spend
10 August, 2004 by Melissa TrudingerPharmaxis (ASX: PXS) has released its preliminary final results, posting a loss of AUD$6 million for the 2003-2004 financial year.
